May 20, 2021 5:13pm

Biostage (BSTG) Chronicles: Another Q reporting MISS - Biostage (BSTG) “could not complete the filing of its Q1 reporting” - Do investors think – something continues to be amiss? Wonder if they’re “cash broke”? <read more>

Pre-open indication performance: 4 HITs and 3 MISS

If you’re looking for sector intel, ideas and facts or numbers (which don’t lie) in a volatile climate, RMi defines the rigors of share pricing! My comments distinguish the temporary from real pricing digression or progress.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

The Dow closed UP +188.11 points (+0.55%); the S&P closed UP +43.44 points (+1.06%) while the Nasdaq closed UP +236.00 points (+1.77%)

 

Henry’omics:

Indexes rose on Thursday, rebounding from three straight days of losses as cell and gene therapy sector shares staged a comeback, while the low jobless claims boosted sentiment.

 

Biostage (BSTG) Chronicles: Another reporting MISS - Biostage (BSTG) SEC filing: “could not complete the filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2021 due to disruptions in staffing. This in turn, delayed the Company’s ability to obtain and compile the information required to be included in the Company's Form 10-Q, which delay could not be eliminated by the Company without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company will file its Form 10-Q no later than the fifth calendar day following the prescribed due date”.  Do investors think – something continues to be amiss? Their interim financial officed did get Q4 and FY20 “numbers” out, is there an issue of “cash position” behind the “hide” or late-filing?

 

Data Docket: Initial claims for jobless benefits totaled 444,000 last week, better than the 452,000 Dow Jones estimate. The total represented a decline from the previous week’s 478,000 and was the lowest since March 14, 2020. Continuing claims rose by 111,000 to 3.75 million, though that number runs a week behind.

 

RegMed Investors’ (RMi) pre-open: “chances of recouping some value as we go from the merry-go-round to the roller-coaster” … https://www.regmedinvestors.com/articles/11919

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Thursday opened positive at 27/5, 2 flats and 1 acquired, stayed positive at the mid-day to 30/3, 1 acquired, closing positive at 28/5, 1 flat and 1 acquired;

 

Pre-open indication results:  4 HITs < Maintain SELL: Biostage (BSTG -$0.00 at $1.30 with 1 share traded); BUY: bluebird bio (BLUE +$1.29), Cellectis SA (CLLS +$0.69), Global Blood Therapeutics (GBT +$1.31) and 3 MISS <SELL: Chinook Therapeutics (KDNY +$0.62), Editas Medicine (EDIT +$1.07), CRISPR Therapeutics (CRSP +$7.09)>

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … to date: https://www.regmedinvestors.com/articles/11628

 

There are clear winners and losers

Jumping with share pricing momentum:

  • CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY), ReNeuron (RENE.L), Ultragenyx (RARE), Sage Therapeutics (SAGE) to name 5 of the 28 inclining of the 35 covered

Hammered in today’s market:

  • Voyager Therapeutics (VYGR), Intellia therapeutics (NTLA), Homology Medicine (FIXX), MiMedx (MDXG), Caladrius Biosciences (CLBS) to name 5 of the 5 declining of the 35 covered

 

Key metrics:

  • Sector volume was LOW with 0 of the 28-upside having higher than the 3-month average volume with the volume of 1 of 5-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 28-upside were +0.38% (AXGN) to +6.41% (CRSP) while the 5-downside ranges from -0.62% (NTLA) to -10.25% (VYGR);

 

Thursday’s (10 of 28) incliners:

  • CRISPR Therapeutics (CRSP +$7.09 after Wednesday’s -$1.88, Tuesday’s +$3.444 and Monday’s +$2.58);
  • Alnylam Pharmaceuticals (ALNY +$5.17);
  • ReNeuron (RENE.L +$3.50 after Wednesday’s -$6.00);
  • Ultragenyx (RARE +$3.22 after Wednesday’s -$2.81, Tuesday’s +$1.14 and Monday’s -$0.59);
  • Sage Therapeutics (SAGE +$2.61 after Wednesday’s -$1.46);
  • Fate Therapeutics (FATE +$1.93 after Wednesday’s -$2.71, Tuesday’s +$1.69 and Monday’s -$0.36);
  • uniQure NV (QURE +$1.91 after Wednesday’s +$0.22, Tuesday’s +$0.86 after Monday’s -$0.73);
  • BioLife Solutions (BLFS +$1.48);
  • Global Blood Therapeutics (GBT +$1.31 after Wednesday’s -$0.86, Tuesday’s +$0.98 and Monday’s +$0.13);
  • bluebird bio (BLUE+$1.29 after Wednesday’s -$1.24, Tuesday’s +$0.76 and Monday’s -$0.41);

Thursday’s (5 of 5) decliners:

  • Voyager Therapeutics (VYGR -$0.45 – management shuffle);
  • Intellia Therapeutics (NTLA -$0.40 after Wednesday’s -$3.11, Tuesday’s -$0.33 and Monday’s -$0.35);
  • MiMedx (MDXG -$0.09 after Wednesday’s +$0.44, Tuesday’s -$0.16 and Monday’s -$0.27);
  • Homology Medicine (FIXX -$0.05);
  • Caladrius Biosciences (CLBS -$0.01);

Closing 1 – Biostage (BSTG) and 1 - Stemline Therapeutics (STML – acquired)

 

COVID-19 updates:

  • Roughly 1.8 million vaccinations have been reported on average each day over the past week, and 48% of the population has received at least one dose.

Wednesday’s COVID Data Tracker <Million>:

  • Cases: 32.85 M
  • Death rate totaled 584,975 - dipping <Johns Hopkins University>
  • Vaccinations:  60.5%

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed +2.03% and XBI closed up +2.10%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -1.510. points or -6.81% at 20.67

Upside volume: low

  • Thursday: 0 out of the 28-upside had higher than the 3-month average volume;

Downside volume: low

  • Thursday: 1 out of the 5-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: LOW % with limited pricing drops as upside maintains

  • Thursday’s percentage (%) of the 28-upside were +0.38% (AXGN) to +6.41% (CRSP) while the 5-downside ranges from -0.62% (NTLA) to -10.25% (VYGR);

 

May, second month of Q2/21:

Thursday closed positive with 28 advancers, 5 decliners, 1 flat and 1 acquired

Wednesday closed negative with 7 advancers, 27 decliners and 1 acquired

Tuesday closed positive with 21 advancers, 11 decliners, 2 flats and 1 acquired

Monday (5/17) closed negative with 14 advancers, 18 decliners, 2 flat and 1 acquired

 

The BOTTOM LINE: Back on the merry-go-round of share price as sentiment turns the upward slide versus yesterday’s downslide.

Q1 earnings season is wrapping up and my reaction to earnings LPS (loss-per-share) results reveals more than some skepticism that Q1 losses provide a reason for additional forward-looking less than optimistic and more pessimism through the mid-year.”

Reiterating, the cell and gene therapy sector has been experiencing “whiplash – again which becomes a recurring event or an accident”.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

My time frame of measurement is Friday to Friday and been proved right again, don’t get complacent …

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.